<DOC>
	<DOCNO>NCT02453776</DOCNO>
	<brief_summary>Infliximab ( IFX ) highly effective induce maintain remission patient inflammatory bowel disease ( IBD ) . However , large proportion patient eventually lose response IFX . Therefore , strategy improve outcome maintenance treatment IFX require . Retrospective analysis suggest adjust IFX treatment order achieve IFX trough level ( TL ) well-defined therapeutic threshold improve outcome IFX treatment .</brief_summary>
	<brief_title>Precision Dosing Infliximab Versus Conventional Dosing Infliximab</brief_title>
	<detailed_description>Aim study investigate efficacy `` precision dosing '' IFX maintenance treatment comparison standard IFX maintenance treatment IBD patient clinical remission . This study open , randomize , control trial . Inclusion criterion : Patients age ≥18 year diagnosis Crohn 's disease ( CD ) ulcerative colitis ( UC ) base endoscopy pathology , receive schedule IFX therapy ≥14 week , clinical remission base Harvey Bradshaw Index ( HBI ) score ≤4 Partial Mayo ( PM ) score ≤2 , CD UC , respectively . Exclusion criterion : Dilatation resectional surgury past year patient stoma/pouch . Patients intervention arm receive individualize treatment variable IFX dose AND/OR interval guide Bayesian pharmacokinetic model , aim achieve IFX TL 3 µg/ml . Patients control group continue receive IFX treatment regimen give prior inclusion without dose adaptation . In control group , treatment adjustment make case sign active disease , accordance current routine care patient consider failure treatment . Primary endpoint : Proportion patient sustain clinical remission ( base HBI PM ) . Secondary endpoint include : annual cost IFX treatment per patient , total annual medical cost , side effect , ( sustain ) biochemical remission , adverse event , quality life , IFX trough level IFX antibody ( assay allow presence drug ) . Nature extent burden risk associate participation , benefit group relatedness : Participation result additional blood sampling , since IFX serum concentration measure every 8 week . All laboratory test consider routine care . Patients intervention group IFX TLs &gt; 3 receive treatment de-escalation ( interval elongation and/or dose reduction ) indicate Baysian model . Current evidence indicate IFX TL 3 suffices . Patients intervention group TLs &lt; 3 receive treatment escalation ( interval shorten and/or dose increase ) . We hypothesize result high chance remain clinical remission .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis CD UC base endoscopy pathology 18 year old Clinical remission , base Harvey Bradshaw Index ( HBI ) score ≤4 Partial Mayo ( PM ) score ≤2 , CD UC Scheduled IFX maintenance treatment , regardless interval/dosing Dilatation resectional surgery stenotic IBD past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Crohns Disease</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Sustained</keyword>
	<keyword>Remission</keyword>
	<keyword>Inflammatory bowel disease</keyword>
	<keyword>IBD</keyword>
</DOC>